irinotecan has been researched along with Glioblastoma with Sarcomatous Component in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brem, H; Moriarity, JL; Renard, VM; Storm, PB; Tyler, B; Weingart, JD; Wilentz, RE | 1 |
1 other study(ies) available for irinotecan and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gliosarcoma; Irinotecan; Neoplasm Transplantation; Rats; Rats, Inbred F344; Topoisomerase I Inhibitors | 2004 |